Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Dacogen

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
UNLABELLED : On September 20, 2012, a marketing authorization valid throughout the European Union (EU) was issued for decitabine… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2015
2015
IntroductionAmong patients with acute myeloid leukemia (AML), the DACO-016 randomized study showed reduction in mortality for… Expand
  • table 1
  • table 2
Is this relevant?
Review
2014
Review
2014
Over the past several years, there has been rapidly expanding evidence of epigenetic dysregulation in cancer, in which histone… Expand
  • figure 1
  • table 1
  • figure 2
Is this relevant?
Review
2011
Review
2011
Boumber and Issa provide a useful review of the development of agents that target the epigenome—primarily DNA methyltransferase… Expand
Is this relevant?
2007
2007
Current Therapy for Acute Myeloid Leukemia Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults… Expand
  • figure 1
Is this relevant?
2006
2006
OBJECTIVE Treatment with the DNA demethylating drug 5-aza-2'-deoxycytidine (Dacogen; DAC) increased fetal hemoglobin and F cells… Expand
Is this relevant?
Review
2005
Review
2005
New therapeutic approaches are being developed for the treatment of cancer patients. Increasingly, drugs are being produced based… Expand
Is this relevant?
2004
2004
The antineoplastic activity of 5-aza-2'-deoxycytidine (5-AZA-CdR) and docetaxel (Taxotere, Taxo) alone or in combination against… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2004
2004
Epigenetic alterations, such as aberrant DNA methylation and histone deacetylation, can silence genes that suppress… Expand
Is this relevant?